Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
    Research Database

    Research Compound Wiki

    Evidence-based profiles for 324 research compounds (peptides, nootropics, SARMs, and growth-hormone secretagogues) with PubMed citations, mechanisms of action, dosing ranges, half-lives, and vendor pricing. See the A–Z list.

    324
    Compounds
    389,582
    PubMed Results
    65
    Categories

    The BodyHackGuide wiki indexes research compounds across 65 major categories. Profiles show PubMed study counts, dosing data from published protocols, and prices from the vendors we track. Compounds are tagged by research stage (preclinical, Phase I-III, approved) and research field (longevity, metabolic, cognitive, recovery, etc.). Nothing here is medical advice. Everything is for research purposes only.

    Most-Studied Compounds

    Ranked by PubMed citation count: the compounds with the deepest peer-reviewed literature base.

    1. 01
      Vitamin DFoundational
      26,928 PubMed results
    2. 02
      ProbioticsSupplement
      24,468 PubMed results
    3. 03
      Omega-3 Fatty AcidsFoundational
      23,154 PubMed results
    4. 04
      CurcuminAntioxidants
      18,445 PubMed results
    5. 05
      MetforminMetabolic
      18,131 PubMed results
    6. 06
      OxytocinHormones & Endocrine (Non-GH)t½ ~1-6 minutes (plasma); central/behavioral effects outlast plasma clearance, typically ~30-120 minutes after intranasal dosing
      13,635 PubMed results
    7. 07
      MelatoninSleep & Circadian
      12,556 PubMed results
    8. 08
      ZincFoundational
      12,524 PubMed results
    9. 09
      RapamycinLongevity
      10,129 PubMed results
    10. 10
      BerberineMetabolic
      8,418 PubMed results

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free

    Adaptogen (17)

    Research compounds in the Adaptogen family, compiled from peer-reviewed literature and clinical trial registries.

    Anabolic Peptide (2)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Antioxidants (2)

    Research compounds in the Antioxidants family, compiled from peer-reviewed literature and clinical trial registries.

    Bioregulator Peptide (4)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Carotenoid (5)

    Research compounds in the Carotenoid family, compiled from peer-reviewed literature and clinical trial registries.

    Cofactor (1)

    Research compounds in the Cofactor family, compiled from peer-reviewed literature and clinical trial registries.

    Cognition, Mood & Neuroprotection (1)

    Research compounds in the Cognition, Mood & Neuroprotection family, compiled from peer-reviewed literature and clinical trial registries.

    Cognitive (6)

    Research compounds in the Cognitive family, compiled from peer-reviewed literature and clinical trial registries.

    Controlled Substances (1)

    Research compounds in the Controlled Substances family, compiled from peer-reviewed literature and clinical trial registries.

    Energy & Performance (1)

    Research compounds in the Energy & Performance family, compiled from peer-reviewed literature and clinical trial registries.

    DMHA

    Energy & PerformanceHistorical pharmaceutical; no modern clinical trials

    DMHA (octodrine) - chemically 2-amino-6-methylheptane, also sold as 2-aminoisoheptane or 1,5-dimethylhexylamine - is an aliphatic-amine central nervous system stimulant and a close structural analog of DMAA (1,3-dimethylamylamine).

    t½ Not formally characterized in humans. After ingestion, octodrine is rapidly metabolized to heptaminol, which becomes the predominant compound detected in blood and urine within hours [PMID:39401652]. Users commonly report perceptible stimulant effects lasting roughly 3-6 hours, but this is anecdotal rather than measured pharmacokinetics. 75-200 mg per dose (anecdotal pre-workout range; ~75,000-200,000 mcg). Historical pharmaceutical unit dose was 8-33 mg. No approved or clinically validated dose exists.
    PreclinicalView Profile

    Enzyme (1)

    Research compounds in the Enzyme family, compiled from peer-reviewed literature and clinical trial registries.

    Essential Nutrient (1)

    Research compounds in the Essential Nutrient family, compiled from peer-reviewed literature and clinical trial registries.

    Flavonoid (4)

    Research compounds in the Flavonoid family, compiled from peer-reviewed literature and clinical trial registries.

    Foundational (13)

    Research compounds in the Foundational family, compiled from peer-reviewed literature and clinical trial registries.

    GH Secretagogue (1)

    Research compounds in the GH Secretagogue family, compiled from peer-reviewed literature and clinical trial registries.

    GLP-1 / Glucagon Dual Agonist (1)

    Research compounds in the GLP-1 / Glucagon Dual Agonist family, compiled from peer-reviewed literature and clinical trial registries.

    Growth Hormone (1)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Growth Hormone / IGF-1 Axis (11)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Hepatoprotective Flavonolignan (1)

    Research compounds in the Hepatoprotective Flavonolignan family, compiled from peer-reviewed literature and clinical trial registries.

    Herbal (8)

    Research compounds in the Herbal family, compiled from peer-reviewed literature and clinical trial registries.

    Hormonal (1)

    Research compounds in the Hormonal family, compiled from peer-reviewed literature and clinical trial registries.

    HCG

    HormonalFDA-approved

    Human chorionic gonadotropin (hCG) is a 237-amino-acid glycoprotein hormone produced naturally during pregnancy by trophoblast cells of the developing embryo, beginning as early as 6-8 days after conception and peaking between weeks 8-11 of gestation at concentrations of 50,000-300,000 mIU/mL maternal serum.

    t½ Approximately 24-36 hours (terminal elimination). Clearance is biphasic: an initial distribution phase of roughly 6-11 hours followed by a terminal phase averaging ~33 hours. This is far longer than pituitary LH (~20-30 minutes), owing to the beta-subunit C-terminal peptide (CTP) and heavy sialylation. Peak plasma concentration occurs ~6-12 hours after SC or IM injection, and a single dose exerts biological effects for roughly 5-7 days. Elimination is primarily renal.
    PreclinicalView Profile

    Hormone (1)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Hormone Support (3)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Clomiphene Citrate

    Hormone SupportPhase 4 (approved drug)

    Clomiphene citrate (clomifene) is a nonsteroidal selective estrogen receptor modulator (SERM) developed by the drug company Merrell and approved by the FDA as Clomid on 1 February 1967 to treat ovulatory dysfunction in women who want to become pregnant (PMID: 35559738; Drugs@FDA NDA 016131; US prescribing information for clomiphene citrate tablets).

    t½ No single value. After one dose in 24 healthy women, zuclomiphene was eliminated much more slowly than enclomiphene and was still detected in plasma a month later (PMID: 3091405), and a 2009 study in women with polycystic ovary syndrome could not calculate a conventional half-life because of a very flat terminal phase (PMID: 19033451). In 12 healthy men who took clomiphene for 30 days, the urinary detection window for zuclomiphene ranged from 121 to more than 261 days (PMID: 30295816).
    PreclinicalView Profile

    T3/T4 Thyroid Blend

    Hormone SupportComponents are FDA-approved prescription drugs (levothyroxine and liothyronine); the fixed-ratio synthetic T3/T4 combination product is investigational/unapproved as sold and is framed here strictly for research use only (RUO).

    A T3/T4 blend pairs two real, FDA-approved thyroid hormones - levothyroxine (T4) and liothyronine (T3) - in a single product, intended to more closely mimic the thyroid gland's natural output than T4 alone.

    t½ T4 (levothyroxine): approximately 6-7 days in euthyroid adults (longer in hypothyroid, shorter in hyperthyroid states). T3 (liothyronine): approximately 1 day (~18-24 hours), which is why T3 is dosed multiple times daily or as a slow-release preparation. Component-split and physician-set, not a fixed self-dose: T4 (levothyroxine) approximately 75-150 mcg/day and T3 (liothyronine) approximately 5-20 mcg/day divided - both titrated to labs (TSH, free T4, free T3), individualized by weight, age and cardiac status. Not a self-dosing recommendation.
    PreclinicalView Profile

    Hormones & Endocrine (Non-GH) (4)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Immune & Inflammation (5)

    Research compounds in the Immune & Inflammation family, compiled from peer-reviewed literature and clinical trial registries.

    Thymulin

    Immune & InflammationNone labelled by phase

    Thymulin is a zinc-dependent nonapeptide hormone made by thymic epithelial cells, purified from pig serum in 1977 by Jean-Francois Bach's group in Paris and first called facteur thymique serique, or FTS (PMID: 303241; PMID: 914862).

    t½ No published human value. In rats, intravenously injected FTS was cleared from blood with a half-life of 2 to 3 minutes (PMID: 8082705). In a single sheep injected with thymulin, serum thymulin fell with a half-life of 10.3 plus or minus 0.6 minutes (PMID: 8040352). Normal human and mouse serum also contains a larger molecule, the size of albumin or prealbumin, that binds FTS and carries it, which the discovery group proposed accounts for FTS-like activity in high molecular weight serum fractions (PMID: 7189463).
    548 PubMedView Profile

    Injury, Repair & Recovery (2)

    Research compounds in the Injury, Repair & Recovery family, compiled from peer-reviewed literature and clinical trial registries.

    BPC-157

    Injury, Repair & RecoveryPreclinical

    BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC.

    t½ Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies
    232 PubMedView Profile

    Isothiocyanate (1)

    Research compounds in the Isothiocyanate family, compiled from peer-reviewed literature and clinical trial registries.

    Liver Support (1)

    Research compounds in the Liver Support family, compiled from peer-reviewed literature and clinical trial registries.

    Liver/Digestive (1)

    Research compounds in the Liver/Digestive family, compiled from peer-reviewed literature and clinical trial registries.

    Longevity (10)

    Research compounds in the Longevity family, compiled from peer-reviewed literature and clinical trial registries.

    Longevity & Cellular Health (2)

    Research compounds in the Longevity & Cellular Health family, compiled from peer-reviewed literature and clinical trial registries.

    Metabolic (9)

    Research compounds in the Metabolic family, compiled from peer-reviewed literature and clinical trial registries.

    Metabolic & Weight Loss (12)

    Research compounds in the Metabolic & Weight Loss family, compiled from peer-reviewed literature and clinical trial registries.

    Mineral (8)

    Research compounds in the Mineral family, compiled from peer-reviewed literature and clinical trial registries.

    Mitochondrial Peptides (1)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Mitochondrial Support (2)

    Research compounds in the Mitochondrial Support family, compiled from peer-reviewed literature and clinical trial registries.

    Myostatin Inhibitor (1)

    Research compounds in the Myostatin Inhibitor family, compiled from peer-reviewed literature and clinical trial registries.

    Nootropic (6)

    Cognitive-enhancing compounds studied for memory, focus, learning, and neuroprotection. Includes racetams, cholinergics like Alpha-GPC, amino-acid derivatives like L-Theanine, and plant adaptogens like Bacopa Monnieri.

    Nootropic Adaptogen (1)

    Cognitive-enhancing compounds studied for memory, focus, learning, and neuroprotection. Includes racetams, cholinergics like Alpha-GPC, amino-acid derivatives like L-Theanine, and plant adaptogens like Bacopa Monnieri.

    Nootropic Lipid (1)

    Cognitive-enhancing compounds studied for memory, focus, learning, and neuroprotection. Includes racetams, cholinergics like Alpha-GPC, amino-acid derivatives like L-Theanine, and plant adaptogens like Bacopa Monnieri.

    Nootropic Peptide (9)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Nootropics (48)

    Cognitive-enhancing compounds studied for memory, focus, learning, and neuroprotection. Includes racetams, cholinergics like Alpha-GPC, amino-acid derivatives like L-Theanine, and plant adaptogens like Bacopa Monnieri.

    Other (10)

    Specialty research compounds spanning lipid modulators, longevity molecules, mitochondrial cofactors, and emerging translational targets.

    B7-33

    OtherPreclinical

    B7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.

    t½ In vitro serum-stability half-life is approximately 6 minutes; B7-33 is rapidly degraded (a lipidated analog extended this to ~60 minutes in the same assay). Human in vivo pharmacokinetics are unpublished, and rapid clearance is expected for a small linear peptide (Praveen et al. 2023, PMID 37047588). 500-4000 mcg subcutaneous per injection (community/self-report research doses; most commonly ~1000 mcg / 1 mg once daily). No validated human dose exists - all figures are empirical extrapolations from rodent pharmacology.
    12 PubMedView Profile

    Peptides (1)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Performance (11)

    Research compounds in the Performance family, compiled from peer-reviewed literature and clinical trial registries.

    Performance & Recovery (1)

    Research compounds in the Performance & Recovery family, compiled from peer-reviewed literature and clinical trial registries.

    Pharmaceutical (12)

    Research compounds in the Pharmaceutical family, compiled from peer-reviewed literature and clinical trial registries.

    Polyamine (1)

    Research compounds in the Polyamine family, compiled from peer-reviewed literature and clinical trial registries.

    Polyphenol (4)

    Research compounds in the Polyphenol family, compiled from peer-reviewed literature and clinical trial registries.

    Protein (1)

    Research compounds in the Protein family, compiled from peer-reviewed literature and clinical trial registries.

    Recovery (17)

    Research compounds in the Recovery family, compiled from peer-reviewed literature and clinical trial registries.

    Reproductive Hormone (1)

    Endocrine signaling molecules and analogues studied across metabolic, reproductive, and performance contexts. Includes thyroid analogues, insulin sensitizers, and HPTA-restoring compounds.

    Senolytics (1)

    Research compounds in the Senolytics family, compiled from peer-reviewed literature and clinical trial registries.

    Skin & Hair (11)

    Research compounds in the Skin & Hair family, compiled from peer-reviewed literature and clinical trial registries.

    Palmitoyl Pentapeptide-4

    Skin & HairMarketed topical cosmetic ingredient with a small set of human cosmetic trials

    Palmitoyl pentapeptide-4 is the cosmetic ingredient Pal-KTTKS, a five-amino-acid fragment of the type I collagen propeptide with a 16-carbon palmitic acid chain attached, sold to formulators under the trade name Matrixyl (PubChem CID 9897237; PMID: 8486721).

    t½ No published human value. The relevant measurements are stability in skin rather than plasma. In hairless mouse skin extracts and homogenates both KTTKS and pal-KTTKS were degraded rapidly, with pal-KTTKS the more stable of the two, and adding protease inhibitors improved the stability of both (PMID: 25143811). In rat skin homogenate the free peptide was described as very susceptible to peptide bond cleavage by aminopeptidases present in the skin (PMID: 22921149).
    35 PubMedView Profile

    Dutasteride

    Skin & HairPhase 3 (approved for benign prostatic hyperplasia; phase 3 trials completed in male androgenetic alopecia, ClinicalTrials.gov NCT00441116 and NCT01231607)

    Dutasteride is a synthetic 4-azasteroid drug that blocks both type 1 and type 2 steroid 5-alpha-reductase, the enzymes that turn testosterone into dihydrotestosterone (DHT); it was developed at Glaxo Wellcome under the code GG745 and approved by the FDA in 2001 as Avodart for benign prostatic hyperplasia (PMID: 9316864; Drugs@FDA NDA 021319; US prescribing information for Avodart).

    t½ About 5 weeks (terminal elimination half-life at steady state in the US prescribing information for Avodart), with serum levels detectable for 4 to 6 months after the last dose; about 240 hours after single doses in Glaxo Wellcome's early human studies (PMID: 9316864).
    PreclinicalView Profile

    Ketoconazole

    Skin & HairApproved drug; no hair-loss trial of ketoconazole is registered on ClinicalTrials.gov (searched 27 October 2026)

    Ketoconazole is a synthetic imidazole antifungal that blocks the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase and so stops the yeast or mold from making ergosterol for its cell membrane; it was the first broad-spectrum oral antifungal approved by the FDA, as Nizoral tablets from Janssen in 1981, and is also sold as 2 percent and 1 percent shampoos, creams and foams (PMID: 25409549; Drugs@FDA NDA 018533; US prescribing information for ketoconazole tablets).

    t½ Oral tablets: elimination from plasma is biphasic, with a half-life of about 2 hours over the first 10 hours and about 8 hours after that (US prescribing information for ketoconazole tablets). Shampoo: ketoconazole was not detected in plasma after long-term shampooing, so no topical half-life has been measured (US prescribing information for ketoconazole 2% shampoo).
    PreclinicalView Profile

    Skin / Cosmetic (1)

    Research compounds in the Skin / Cosmetic family, compiled from peer-reviewed literature and clinical trial registries.

    Skin, Hair & Aesthetics (3)

    Research compounds in the Skin, Hair & Aesthetics family, compiled from peer-reviewed literature and clinical trial registries.

    Sleep (1)

    Research compounds in the Sleep family, compiled from peer-reviewed literature and clinical trial registries.

    Sleep & Circadian (2)

    Research compounds in the Sleep & Circadian family, compiled from peer-reviewed literature and clinical trial registries.

    Stilbene Polyphenol (1)

    Research compounds in the Stilbene Polyphenol family, compiled from peer-reviewed literature and clinical trial registries.

    Supplement (8)

    Research compounds in the Supplement family, compiled from peer-reviewed literature and clinical trial registries.

    Supplies (1)

    Research compounds in the Supplies family, compiled from peer-reviewed literature and clinical trial registries.

    Tanning Peptide (1)

    Short chains of amino acids that signal specific receptors. Research peptides range from healing compounds like BPC-157 and TB-500 to growth-hormone secretagogues like Ipamorelin and Tesamorelin, and GLP-1 agonists like Semaglutide and Retatrutide.

    Vitamin (9)

    Research compounds in the Vitamin family, compiled from peer-reviewed literature and clinical trial registries.

    Weight Loss (11)

    Research compounds in the Weight Loss family, compiled from peer-reviewed literature and clinical trial registries.

    herb (4)

    Research compounds in the herb family, compiled from peer-reviewed literature and clinical trial registries.

    Browse Full Database

    Filter by category, research phase, and research field, or use the search bar at the top of the page.

    Sort
    Category
    Phase
    Field

    324 compounds in database

    Thymulin

    Immune & InflammationNone labelled by phase

    Thymulin is a zinc-dependent nonapeptide hormone made by thymic epithelial cells, purified from pig serum in 1977 by Jean-Francois Bach's group in Paris and first called facteur thymique serique, or FTS (PMID: 303241; PMID: 914862).

    t½ No published human value. In rats, intravenously injected FTS was cleared from blood with a half-life of 2 to 3 minutes (PMID: 8082705). In a single sheep injected with thymulin, serum thymulin fell with a half-life of 10.3 plus or minus 0.6 minutes (PMID: 8040352). Normal human and mouse serum also contains a larger molecule, the size of albumin or prealbumin, that binds FTS and carries it, which the discovery group proposed accounts for FTS-like activity in high molecular weight serum fractions (PMID: 7189463).
    548 PubMedView Profile

    BPC-157

    Injury, Repair & RecoveryPreclinical

    BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC.

    t½ Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies
    232 PubMedView Profile

    Palmitoyl Pentapeptide-4

    Skin & HairMarketed topical cosmetic ingredient with a small set of human cosmetic trials

    Palmitoyl pentapeptide-4 is the cosmetic ingredient Pal-KTTKS, a five-amino-acid fragment of the type I collagen propeptide with a 16-carbon palmitic acid chain attached, sold to formulators under the trade name Matrixyl (PubChem CID 9897237; PMID: 8486721).

    t½ No published human value. The relevant measurements are stability in skin rather than plasma. In hairless mouse skin extracts and homogenates both KTTKS and pal-KTTKS were degraded rapidly, with pal-KTTKS the more stable of the two, and adding protease inhibitors improved the stability of both (PMID: 25143811). In rat skin homogenate the free peptide was described as very susceptible to peptide bond cleavage by aminopeptidases present in the skin (PMID: 22921149).
    35 PubMedView Profile

    FOXO4-DRI

    RecoveryPreclinical

    FOXO4-DRI is a synthetic 46-amino-acid D-retro-inverso peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53, with the specific goal of inducing apoptosis selectively in senescent cells.

    t½ Not established in humans; no published human pharmacokinetic data. The D-retro-inverso construction confers resistance to human proteases, which in preclinical models extends the in vivo half-life from minutes (typical for comparable L-amino-acid peptides) to hours ([Baar et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28340339/)). No validated human dose. Self-report: 2-15 mg SC per dose (typically 5 mg), pulsed 3-7 days every 2-6 months; no human PK data. The 5 mg/kg figure seen in some sources is a mouse research dose (Baar 2017), not a human dose.
    19 PubMedView Profile

    Pinealon

    NootropicsPreclinical

    Pinealon is a synthetic tripeptide — glutamyl-aspartyl-arginine (Glu-Asp-Arg, or EDR) — developed by the St Petersburg Institute of Bioregulation and Gerontology (IBG) under the leadership of Professor Vladimir Khavinson, the dominant figure in what is collectively known as the "Russian short-peptide bioregulator" school of research.

    t½ Not formally characterized in humans. Short regulatory peptides of this class are cleared from plasma within minutes; the Khavinson framework proposes durable downstream gene-expression effects that outlast the brief dosing window, which is the stated rationale for pulsed cycling rather than continuous dosing. Subcutaneous (primary route): 2-10 mg/day, typically 3-5 mg, in pulsed 10-20 day cycles, 2-4 cycles/year. Intranasal: 150-800 mcg per nostril daily. Research use only; oral dosing is not recommended because the peptide is largely degraded by GI proteases.
    18 PubMedView Profile

    B7-33

    OtherPreclinical

    B7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.

    t½ In vitro serum-stability half-life is approximately 6 minutes; B7-33 is rapidly degraded (a lipidated analog extended this to ~60 minutes in the same assay). Human in vivo pharmacokinetics are unpublished, and rapid clearance is expected for a small linear peptide (Praveen et al. 2023, PMID 37047588). 500-4000 mcg subcutaneous per injection (community/self-report research doses; most commonly ~1000 mcg / 1 mg once daily). No validated human dose exists - all figures are empirical extrapolations from rodent pharmacology.
    12 PubMedView Profile

    PE-22-28

    NootropicsPreclinical

    PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an analog of Humanin with specific interest in activity at glutamate transporter regulation and cytoprotective signaling relevant to depression and neuroprotection.

    t½ Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg).
    3 PubMedView Profile

    Clomiphene Citrate

    Hormone SupportPhase 4 (approved drug)

    Clomiphene citrate (clomifene) is a nonsteroidal selective estrogen receptor modulator (SERM) developed by the drug company Merrell and approved by the FDA as Clomid on 1 February 1967 to treat ovulatory dysfunction in women who want to become pregnant (PMID: 35559738; Drugs@FDA NDA 016131; US prescribing information for clomiphene citrate tablets).

    t½ No single value. After one dose in 24 healthy women, zuclomiphene was eliminated much more slowly than enclomiphene and was still detected in plasma a month later (PMID: 3091405), and a 2009 study in women with polycystic ovary syndrome could not calculate a conventional half-life because of a very flat terminal phase (PMID: 19033451). In 12 healthy men who took clomiphene for 30 days, the urinary detection window for zuclomiphene ranged from 121 to more than 261 days (PMID: 30295816).
    PreclinicalView Profile

    DMHA

    Energy & PerformanceHistorical pharmaceutical; no modern clinical trials

    DMHA (octodrine) - chemically 2-amino-6-methylheptane, also sold as 2-aminoisoheptane or 1,5-dimethylhexylamine - is an aliphatic-amine central nervous system stimulant and a close structural analog of DMAA (1,3-dimethylamylamine).

    t½ Not formally characterized in humans. After ingestion, octodrine is rapidly metabolized to heptaminol, which becomes the predominant compound detected in blood and urine within hours [PMID:39401652]. Users commonly report perceptible stimulant effects lasting roughly 3-6 hours, but this is anecdotal rather than measured pharmacokinetics. 75-200 mg per dose (anecdotal pre-workout range; ~75,000-200,000 mcg). Historical pharmaceutical unit dose was 8-33 mg. No approved or clinically validated dose exists.
    PreclinicalView Profile

    Dutasteride

    Skin & HairPhase 3 (approved for benign prostatic hyperplasia; phase 3 trials completed in male androgenetic alopecia, ClinicalTrials.gov NCT00441116 and NCT01231607)

    Dutasteride is a synthetic 4-azasteroid drug that blocks both type 1 and type 2 steroid 5-alpha-reductase, the enzymes that turn testosterone into dihydrotestosterone (DHT); it was developed at Glaxo Wellcome under the code GG745 and approved by the FDA in 2001 as Avodart for benign prostatic hyperplasia (PMID: 9316864; Drugs@FDA NDA 021319; US prescribing information for Avodart).

    t½ About 5 weeks (terminal elimination half-life at steady state in the US prescribing information for Avodart), with serum levels detectable for 4 to 6 months after the last dose; about 240 hours after single doses in Glaxo Wellcome's early human studies (PMID: 9316864).
    PreclinicalView Profile

    HCG

    HormonalFDA-approved

    Human chorionic gonadotropin (hCG) is a 237-amino-acid glycoprotein hormone produced naturally during pregnancy by trophoblast cells of the developing embryo, beginning as early as 6-8 days after conception and peaking between weeks 8-11 of gestation at concentrations of 50,000-300,000 mIU/mL maternal serum.

    t½ Approximately 24-36 hours (terminal elimination). Clearance is biphasic: an initial distribution phase of roughly 6-11 hours followed by a terminal phase averaging ~33 hours. This is far longer than pituitary LH (~20-30 minutes), owing to the beta-subunit C-terminal peptide (CTP) and heavy sialylation. Peak plasma concentration occurs ~6-12 hours after SC or IM injection, and a single dose exerts biological effects for roughly 5-7 days. Elimination is primarily renal.
    PreclinicalView Profile

    Ketoconazole

    Skin & HairApproved drug; no hair-loss trial of ketoconazole is registered on ClinicalTrials.gov (searched 27 October 2026)

    Ketoconazole is a synthetic imidazole antifungal that blocks the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase and so stops the yeast or mold from making ergosterol for its cell membrane; it was the first broad-spectrum oral antifungal approved by the FDA, as Nizoral tablets from Janssen in 1981, and is also sold as 2 percent and 1 percent shampoos, creams and foams (PMID: 25409549; Drugs@FDA NDA 018533; US prescribing information for ketoconazole tablets).

    t½ Oral tablets: elimination from plasma is biphasic, with a half-life of about 2 hours over the first 10 hours and about 8 hours after that (US prescribing information for ketoconazole tablets). Shampoo: ketoconazole was not detected in plasma after long-term shampooing, so no topical half-life has been measured (US prescribing information for ketoconazole 2% shampoo).
    PreclinicalView Profile

    ProVigorous Blend

    PerformanceNo published studies of the blend; ingredients studied separately

    ProVigorous Blend is a liquid sold for research in a 20 mL vial whose label lists L-arginine 100 mg, L-citrulline 100 mg, L-carnitine 250 mg/mL, an MIC complex of methionine, inositol and choline 120 mg/mL, N-acetyl-L-tyrosine 20 mg, ATP 40 mg and AMP 5 mg/mL.

    t½ No published human value for ProVigorous Blend. Values for single ingredients: after a slow intravenous injection of levocarnitine, the apparent terminal elimination half-life was 17.4 hours, uncorrected for the body's own carnitine (Carnitor label, FDA); after 30-hour intravenous ATP infusions in lung cancer patients, the extra ATP in red blood cells disappeared with a half-time of about 5.9 hours, measured in 5 patients (PMID: 10853877).
    PreclinicalView Profile

    Riboflavin

    VitaminDietary Supplement (Food Ingredient)

    Riboflavin (vitamin B2) is a water-soluble vitamin that serves as the precursor to two universal flavoprotein cofactors — flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) — which together serve as electron-carrying prosthetic groups in more than 90 human enzymes including Complex I and Complex II of the mitochondrial electron transport chain, the acyl-CoA dehydrogenases of fatty acid β-oxidation, glutathione reductase (the enzyme that regenerates reduced glutathione for antioxidant defense), methylenetetrahydrofolate reductase (MTHFR, the critical folate cycle enzyme), pyridoxine-5-phosphate oxidase (PNPO, which converts dietary B6 vitamers to active PLP), and kynurenine monooxygenase in the tryptophan-to-NAD+ pathway.

    PreclinicalView Profile

    Selegiline

    PharmaceuticalPhase 4 (approved drug)

    Selegiline, also called L-deprenyl or (-)-deprenyl, is an irreversible inhibitor of the enzyme monoamine oxidase B (MAO-B), created in the 1960s by Joseph Knoll of Semmelweis University in Budapest and approved by the FDA in 1989 (labeled as an add-on to levodopa in Parkinson's disease) and in 2006 as the Emsam skin patch for major depressive disorder in adults (PMID: 27480491, PMID: 3147347; Drugs@FDA NDA 019334, NDA 021336; US prescribing information for selegiline hydrochloride tablets; US prescribing information for Emsam).

    t½ About 2 hours after a single oral dose and about 10 hours at steady state (US prescribing information for selegiline hydrochloride tablets); the Emsam label gives no half-life for the patch itself and reports 18 to 25 hours for selegiline and its three main metabolites after an intravenous dose (US prescribing information for Emsam). Because the enzyme is inhibited irreversibly, brain MAO-B recovered with a half-time of about 40 days after selegiline was stopped in a PET study (PMID: 7839316).
    PreclinicalView Profile

    Spironolactone

    Skin & HairPhase 3 (approved drug; acne use tested in the phase 3 SAFA trial, ISRCTN12892056)

    Spironolactone is a synthetic steroid that blocks the aldosterone (mineralocorticoid) receptor and also acts as an antiandrogen; it was first approved by the FDA on 21 January 1960 as Aldactone tablets and is a prescription diuretic for heart failure, high blood pressure, edema and primary hyperaldosteronism (PMID: 19370553, PMID: 36923692; Drugs@FDA NDA 012151; US prescribing information for Aldactone).

    t½ About 1.4 hours for spironolactone itself, with longer-lasting active metabolites: 16.5 hours for canrenone and 13.8 hours for 7-alpha-thiomethylspirolactone after 15 days of dosing in 12 healthy men (PMID: 2723123). The US prescribing information for Aldactone gives the same values.
    PreclinicalView Profile

    T3/T4 Thyroid Blend

    Hormone SupportComponents are FDA-approved prescription drugs (levothyroxine and liothyronine); the fixed-ratio synthetic T3/T4 combination product is investigational/unapproved as sold and is framed here strictly for research use only (RUO).

    A T3/T4 blend pairs two real, FDA-approved thyroid hormones - levothyroxine (T4) and liothyronine (T3) - in a single product, intended to more closely mimic the thyroid gland's natural output than T4 alone.

    t½ T4 (levothyroxine): approximately 6-7 days in euthyroid adults (longer in hypothyroid, shorter in hyperthyroid states). T3 (liothyronine): approximately 1 day (~18-24 hours), which is why T3 is dosed multiple times daily or as a slow-release preparation. Component-split and physician-set, not a fixed self-dose: T4 (levothyroxine) approximately 75-150 mcg/day and T3 (liothyronine) approximately 5-20 mcg/day divided - both titrated to labs (TSH, free T4, free T3), individualized by weight, age and cardiac status. Not a self-dosing recommendation.
    PreclinicalView Profile

    Last updated: November 18, 2026

    Research drops

    Get the research before it hits Reddit.

    New compound profiles, dosing guides and the studies worth reading. Sent on no set schedule.

    Unsubscribe anytime. We never share your email.

    © 2026 BodyHackGuide · Research purposes only.